[ET Net News Agency, 18 May 2022] CSPC Pharmaceutical Group Limited (01093) said the
"Doxofylline Injection (10ml:0.1g)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a
subsidiary of the company, has obtained drug registration approval granted by the National
Medical Products Administration of the People's Republic of China and is deemed to have
passed the consistency of quality and efficacy evaluation of generic drugs.
Doxofylline is a methylxanthine derivative with anti-asthmatic effects by the inhibition
of phosphodiesterase enzymes in smooth muscle cells which results in bronchial smooth
muscle relaxation. As a bronchodilator, the product is indicated for the treatment of
shortness of breath caused by bronchial asthma, chronic asthmatic bronchitis and
bronchospasm. (RC)